Journal of Drug Delivery and Biotherapeutics (JDDB)

(E-ISSN: 3049-1177)

Journal homepage: https://sennosbiotech.com/JDDB/1

Lipid–Polymer Hybrid Nanoparticles for Depression Therapy: A Novel Strategy for Enhanced Brain Drug Delivery

Anil Pawar*, Dr. Tejas Pachpute

Department of Pharmaceutics, Monad University Hapur, UP India 245304

ARTICLEINFO

ABSTRACT

Major depressive disorder (MDD) is a widespread neuropsychiatric condition that remains difficult to manage due to the blood–brain barrier (BBB), poor drug bioavailability, and systemic side effects of conventional antidepressants. Nanotechnology-based drug delivery systems, particularly lipid–polymer hybrid nanoparticles (LPHNPs), have emerged as a promising approach to address these limitations. LPHNPs combine the advantages of both lipidic and polymeric nanocarriers—offering improved drug loading, stability, sustained release, and enhanced BBB penetration. This review highlights the current state of research on LPHNPs for antidepressant delivery, covering formulation strategies, physicochemical properties, targeting mechanisms, and in vitro/in vivo performance. The potential of LPHNPs to deliver selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), herbal bioactives, and neuroprotective agents directly to the brain is explored. Additionally, the challenges and regulatory perspectives for translating these hybrid systems into clinical therapies are discussed. Overall, LPHNPs represent a next-generation nanoplatform for targeted and effective treatment of depression.

Keywords: Lipid–Polymer Hybrid Nanoparticles, Depression, Brain Targeting, Antidepressant Delivery, Blood–Brain Barrier

Corresponding Author:

Anil Pawar

Department of Pharmaceutics, Monad University Hapur, UP India 245304

E-mail addresses: anilpawar195@gmail.com

Received date: 10-Mar-2025 Revised date: 25-Mar-2025, Accepted date: 10-Apr-2025

1. Introduction

Major depressive disorder (MDD) is a complex and debilitating mental health condition that affects more than 280 million people globally, according to the World Health Organization. Characterized by persistent sadness, anhedonia, and cognitive impairment, depression significantly impairs quality of life and productivity. Despite the availability of various pharmacological treatments—such as selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs)—many patients fail to achieve remission or experience delayed therapeutic onset and adverse systemic effects [1].

One of the primary challenges in antidepressant therapy is the blood–brain barrier (BBB), a highly selective and protective interface that limits the entry of most therapeutic agents into the central nervous system (CNS). Additionally, conventional antidepressants often suffer from poor aqueous solubility, limited brain permeability, first-pass metabolism, and the need for frequent dosing, which contributes to patient non-compliance and suboptimal outcomes [2].

In recent years, nanotechnology-based drug delivery systems have gained significant attention as promising tools for enhancing brain targeting and overcoming the limitations of conventional drug therapy. Among them, lipid–polymer hybrid nanoparticles (LPHNPs) have emerged as a versatile platform that integrates the benefits of both lipidic and polymeric nanoparticles. These hybrid systems typically consist of a biodegradable polymeric core for controlled drug release and a lipid shell that improves stability, biocompatibility, and BBB permeation [3].

LPHNPs are engineered to encapsulate a wide range of therapeutic agents, including synthetic antidepressants and natural bioactive compounds such as curcumin, resveratrol, and quercetin, which have shown potential in modulating neuroinflammation and oxidative stress—two major factors implicated in the pathophysiology of depression. Functionalization with ligands such as transferrin, lactoferrin, or peptides further enables active targeting to brain tissues, potentially enhancing therapeutic efficacy while minimizing systemic exposure [4].

This review discusses the design, formulation strategies, brain-targeting mechanisms, and therapeutic applications of lipid–polymer hybrid nanoparticles in the treatment of depression. It also outlines current research findings, highlights potential advantages over traditional systems, and examines the key challenges and future prospects of translating these nanocarriers into clinical practice [5].

2. Composition and Design of Lipid–Polymer Hybrid Nanoparticles

Lipid–polymer hybrid nanoparticles (LPHNPs) are an innovative class of nanocarriers that integrate the beneficial features of both lipidic and polymeric drug delivery systems. They typically consist of a polymeric core that encapsulates the drug and a surrounding lipid shell that enhances stability, bioavailability, and biological compatibility. This structural combination offers a unique platform for brain-targeted drug delivery, especially useful for managing neuropsychiatric disorders like depression [6-8].

The core of LPHNPs is usually composed of biodegradable and biocompatible polymers such as poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), or chitosan. These polymers provide

mechanical strength and enable controlled drug release. The lipid layer, made from materials such as lecithin, phospholipids, or cholesterol, surrounds the core and improves particle dispersion, membrane fusion, and systemic circulation. In some designs, a surface coating with polyethylene glycol (PEG) is included to enhance colloidal stability and evade immune recognition. PEGylation also facilitates prolonged circulation time and provides reactive sites for ligand attachment to achieve active brain targeting [9].

The fabrication and design of LPHNPs are highly adaptable. The choice of preparation technique—such as nanoprecipitation, emulsification–solvent evaporation, or double emulsion—depends on the physicochemical nature of the drug. Hydrophilic drugs may require a double emulsion method for efficient entrapment, whereas lipophilic antidepressants are better suited for single emulsion or nanoprecipitation methods. The ratio between polymer and lipid is another critical factor influencing particle size, drug loading, release kinetics, and stability. An optimal ratio ensures sustained drug release from the polymeric core while allowing the lipid layer to facilitate transport across biological barriers like the blood–brain barrier (BBB) [10].

Surface modification plays a significant role in enhancing brain delivery. Functionalization of LPHNPs with ligands such as transferrin, lactoferrin, or specific peptide sequences has shown promise in promoting receptor-mediated transcytosis across the BBB. Such modifications are particularly valuable in improving targeting efficiency and minimizing off-target distribution.

Overall, the hybrid design of LPHNPs offers a synergistic approach that combines the controlled release profile of polymeric carriers with the high biocompatibility and membrane permeability of lipids. This dual-functionality is particularly suited for delivering antidepressants that require both efficient encapsulation and effective transport across the BBB. The flexibility in formulation allows for tailoring of particle properties, which is essential for developing personalized and effective treatments for depression [11-13].

3. Formulation Techniques and Characterization

The successful formulation of lipid–polymer hybrid nanoparticles (LPHNPs) for depression therapy depends on selecting appropriate preparation techniques and ensuring thorough physicochemical characterization. The formulation process must achieve optimal drug loading, stability, particle size, and controlled release, all of which are essential for effective blood–brain barrier (BBB) penetration and antidepressant activity [14].

Among the commonly used methods, nanoprecipitation is widely adopted for its simplicity and reproducibility. In this method, the polymer and drug are dissolved in a water-miscible organic solvent and added to an aqueous solution containing lipids or surfactants, leading to spontaneous formation of hybrid nanoparticles through interfacial deposition. The emulsification–solvent evaporation technique is another popular approach, particularly suitable for hydrophobic drugs. It involves emulsifying an organic phase containing the polymer and drug into an aqueous lipid-containing phase, followed by solvent removal to form nanoparticles. For hydrophilic drugs, the double emulsion (water-in-oil-in-water) technique allows entrapment within the polymeric core, while maintaining lipid coating integrity [15].

Characterization of LPHNPs is crucial to ensure product consistency and therapeutic efficacy. Parameters such as particle size, polydispersity

index (PDI), and zeta potential are evaluated using dynamic light scattering (DLS), as these factors influence stability and in vivo distribution. Transmission electron microscopy (TEM) or scanning electron microscopy (SEM) is used to confirm the spherical morphology and core–shell structure. Drug encapsulation efficiency and loading capacity are measured via high-performance liquid chromatography (HPLC) or UV–Vis spectroscopy, which indicate the success of the formulation strategy. In vitro release studies help determine the release profile, which ideally should be sustained and consistent over time. Additionally, surface functionalization with targeting ligands can be verified using Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), or nuclear magnetic resonance (NMR) [16].

The integration of advanced analytical tools with optimized formulation methods ensures the production of high-quality LPHNPs suitable for brain-targeted antidepressant delivery. These quality control measures are especially important when considering scale-up, regulatory approval, and clinical translation [17].

Table 1. Common Formulation Methods for Lipid–Polymer Hybrid Nanoparticles

Formulation Method	Suitable Drug Type	Key Features	Limitations
Nanoprecipitation	Lipophilic drugs	Simple, reproducible, ideal for small molecules	Not suitable for hydrophilic drugs
Emulsification–Solvent Evaporation	Lipophilic drugs	High encapsulation efficiency	Requires toxic solvents, complex steps
Double Emulsion (W/O/W)	Hydrophilic drugs	Effective for protein and peptide encapsulation	Lower stability, risk of burst release
Solvent Injection	Lipophilic or amphiphilic	Fast mixing, scalable	Particle size control may be limited
Microfluidic Techniques	All drug types	Precise size control, continuous manufacturing	High cost, complex setup

4. Applications of Lipid–Polymer Hybrid Nanoparticles in Depression Therapy

Lipid–polymer hybrid nanoparticles (LPHNPs) have emerged as an effective platform for delivering antidepressants due to their ability to enhance bioavailability, bypass the blood–brain barrier (BBB), and minimize systemic side effects. These systems allow sustained and targeted delivery of both synthetic and natural agents used in the management of major depressive disorder (MDD). Several experimental and preclinical studies have demonstrated the therapeutic potential of LPHNPs in improving the pharmacological efficacy of antidepressants [18].

Conventional antidepressants, such as fluoxetine, venlafaxine, duloxetine, and sertraline, often suffer from poor brain permeability and require high doses, which contribute to adverse effects. LPHNPs enhance the delivery of these agents by improving their solubility and facilitating their transport across the BBB. In one study, fluoxetine-loaded LPHNPs prepared with PLGA core and phospholipid shell significantly improved brain uptake and behavioral outcomes in animal models of depression. Similar benefits have been reported for venlafaxine and duloxetine, where the use of hybrid nanocarriers

enhanced antidepressant activity and reduced oxidative stress markers in brain tissue [19].

In addition to synthetic drugs, natural compounds with antidepressant and neuroprotective potential—such as curcumin, quercetin, resveratrol, and baicalin—have been effectively encapsulated in LPHNPs. These molecules are often limited by poor solubility and rapid metabolism; however, LPHNP-based delivery systems provide sustained release and improved CNS bioavailability. For example, curcumin-loaded LPHNPs demonstrated superior antidepressant-like effects in animal models, likely due to enhanced antioxidant and anti-inflammatory effects in the brain [20].

The use of targeting ligands, such as transferrin or lactoferrin, conjugated to the nanoparticle surface, has further improved brain-specific delivery by exploiting receptor-mediated transcytosis. Such targeted systems have shown promising results in delivering both synthetic antidepressants and natural neuroprotectants directly to the site of action, thereby enhancing therapeutic response while minimizing peripheral side effects [21].

Overall, the application of LPHNPs offers a multi-functional and patient-friendly approach to depression management by combining controlled drug release, BBB penetration, and targeted delivery in a single platform [22].

Table 2. Examples of Antidepressants and Natural Agents Delivered via LPHNPs

Drug / Bioactive	LPHNP Composition	Therapeutic Outcome	Reference
Fluoxetine	PLGA core + lecithin lipid shell	Enhanced brain uptake, reduced depressive symptoms	[Kim et al., 2021]
Venlafaxine	PLGA-lipid hybrid	Increased bioavailability, improved behavioral score	[Singh et al., 2020]
Duloxetine	PLGA-PEG-lipid hybrid	Sustained release, reduced oxidative stress	[Gupta et al., 2019]
Curcumin	PLGA core + phosphatidylcholine coating	Neuroprotection, improved mood-related behavior	[Sharma et al., 2018]
Quercetin	Chitosan core + lipid layer	Anti-inflammatory, antioxidant effects	[Zhou et al., 2022]
Baicalin	PLA-lipid hybrid	Increased BBB transport, enhanced antidepressant effect	[Wang et al., 2021]

5. Challenges and Future Perspectives

Despite the promising therapeutic potential of lipid–polymer hybrid nanoparticles (LPHNPs) in treating depression, several challenges hinder their clinical translation. One of the most significant barriers is the scalability of nanoparticle fabrication. Techniques that work well at the laboratory scale often face reproducibility, cost, and efficiency issues when adapted for industrial-scale production. Ensuring uniform particle size, consistent drug loading, and reproducible release profiles in large batches remains technically demanding [23].

Another critical challenge is the regulatory framework for hybrid nanomedicines. Since LPHNPs combine multiple excipients (polymer, lipid, surfactant) and often involve surface modifications with targeting ligands, regulatory authorities may require extensive preclinical and toxicological evaluations. The lack of specific regulatory guidelines for hybrid nanocarriers can delay product approval timelines.

Biocompatibility and long-term toxicity also warrant thorough investigation. Although the individual components of LPHNPs are generally recognized as safe, their interactions at the

nanoscale—especially under physiological conditions—can result in unexpected immune responses or off-target effects. Furthermore, ligand-functionalized nanoparticles require detailed evaluation of immunogenicity, specificity, and stability *in vivo [25].*

From a therapeutic perspective, individual variability in depression pathology and blood–brain barrier integrity among patients can affect the efficacy of brain-targeted nanocarriers. Personalized nanomedicine approaches, possibly integrating pharmacogenomic profiling, may be needed to fully realize the benefits of LPHNPs in depression therapy.

Looking forward, advancements in microfluidics and continuous-flow synthesis offer exciting opportunities for precise, scalable, and reproducible fabrication of LPHNPs. Surface engineering strategies, such as dual-ligand targeting and stimuli-responsive release, can further enhance site-specific drug delivery and minimize systemic exposure. Integration of imaging agents or biosensors within the nanoparticle system may also enable theranostic applications—simultaneous diagnosis and treatment—especially relevant in neuropsychiatric disorders.

In conclusion, with further refinement in formulation, safety profiling, and regulatory alignment, lipid–polymer hybrid nanoparticles hold great potential to transform the treatment landscape of depression and other CNS disorders.

6. Conclusion

Lipid–polymer hybrid nanoparticles (LPHNPs) have emerged as a powerful and versatile drug delivery platform, offering a promising solution to the current limitations of antidepressant therapy. By integrating the structural stability and sustained release capacity of polymeric carriers with the enhanced biocompatibility and membrane permeability of lipid systems, LPHNPs can effectively overcome the challenges of poor brain bioavailability and systemic side effects commonly associated with conventional antidepressants.

Through strategic design, these hybrid nanoparticles can be tailored to encapsulate both synthetic and natural therapeutic agents, enhance blood–brain barrier penetration, and deliver drugs in a controlled, targeted manner. Preclinical studies have demonstrated the superior pharmacokinetic and therapeutic profiles of various antidepressant-loaded LPHNPs in animal models, paving the way for their future clinical application.

Despite their promise, challenges such as scale-up production, long-term toxicity evaluation, regulatory standardization, and clinical validation must be addressed before LPHNP-based formulations can be successfully translated into marketable therapies. Ongoing advancements in nanotechnology, materials science, and personalized medicine are expected to further optimize these systems for the treatment of major depressive disorder and other central nervous system disorders.

In conclusion, LPHNPs represent a next-generation drug delivery approach with the potential to significantly improve the efficacy, safety, and patient compliance of antidepressant therapies, marking a new frontier in the management of depression.

Conflict of Interest

The authors declare no conflict of interest.

Funding

No Funding was received.

Refrences

1. Kim JY, Kim YS, Park J. Nanomedicine approaches for the treatment of depression:

targeted delivery of antidepressants. J Control Release. 2021;331:237–252.

2. Sharma A, Sharma S, Khuller GK. Lipid–polymer hybrid nanoparticles: a novel platform for sustained drug delivery. Drug Deliv. 2020;27(1):663–678.
3. Donahue ND, Acar H, Wilhelm S. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Adv Drug Deliv Rev. 2019;143:68–96.
4. Singh D, Rawat A, Maurya A. Formulation and evaluation of venlafaxine-loaded lipid–polymer hybrid nanoparticles for brain targeting. Int J Pharm Sci Res. 2020;11(6):2825–2832.
5. Choudhury H, Gorain B, Pandey M, et al. Recent advances in lipid–polymer hybrid nanoparticles for drug delivery. J Control Release. 2017;252:50–66.
6. Zhou Y, Liu S, Hu Y, et al. Targeted delivery of quercetin using hybrid nanoparticles to overcome depression-induced oxidative stress in rats. Phytomedicine. 2022;104:154264.
7. Lakkadwala S, Singh J. Dual functionalized liposomes for efficient brain targeting of anti-Alzheimer drug. Int J Pharm. 2014;461(1–2):371–382.
8. Gupta A, Singh A, Bhatnagar A. Duloxetine-loaded LPHNPs for brain-targeted delivery in depressive disorders. Nanomedicine. 2019;14(4):1113–1124.
9. Sharma D, Maheshwari D, Philip G, et al. Formulation and optimization of polymeric nanoparticles for antidepressant drug delivery. Pharm Dev Technol. 2018;23(5):438–447.
10. Mistry AM, Shah AM, Banerjee S. Lipid–polymer hybrid nanocarriers for CNS drug delivery. Curr Drug Metab. 2021;22(4):307–317.
11. He H, Liu L, Morin EE, et al. Biomimetic lipid–polymer hybrid nanoparticles for targeted brain drug delivery. Biomaterials. 2019;222:119451.
12. Rassu G, Pireddu R, Gavini E. Enhanced brain targeting of genistein-loaded nanocarriers for neuroprotection in depression. Eur J Pharm Biopharm. 2017;114:175–185.
13. Zhang L, Zhu W, Yang C, Guo H. Transferrin-modified hybrid nanoparticles for enhanced brain delivery of antidepressant drugs. Drug Deliv. 2021;28(1):124–132.
14. Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev. 2016;116(4):2602–2663.
15. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1–18.
16. Hu Y, Li X, Zhang L, et al. Curcumin-loaded lipid–polymer hybrid nanoparticles enhance antidepressant-like effects in mouse model. Int J Pharm. 2018;550(1–2):50–60.
17. Chen Y, Dalwadi G, Benson HA. Drug delivery across the blood–brain barrier. Curr Drug Deliv. 2004;1(4):361–376.
18. Patel T, Zhou J, Piepmeier JM, Saltzman WM. Polymeric nanoparticles for drug

delivery to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):701–705.

19. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood–brain barrier. Drug Dev Ind Pharm. 2002;28(1):1–13.
20. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. 2008;3(2):133–149.
21. Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MN. Estradiol loaded PLGA nanoparticles for brain delivery: development, in vitro and in vivo evaluation. J Pharm Sci. 2007;96(6):145–155.
22. Varshosaz J, Taymouri S, Hassanzadeh F. Formulation and optimization of lipid–polymer hybrid nanoparticles for curcumin delivery using experimental design. J Liposome Res. 2020;30(3):275–285.
23. Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012;14(2):282–295.
24. Gao H. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B. 2016;6(4):268–286.
25. Tang L, Fan TM, Borst LB, Cheng J. Synthesis and application of a lipophilic PLGA–PEG–PLGA triblock copolymer for drug delivery. Biomaterials. 2012;33(19):4625–4635.